Trial Profile

A Randomized, Double-blind, Dose-exploring, Placebo-controlled, Multi-center Phase II Clinical Trial Evaluating the Safety and Immunogenicity of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs COVID-19 mRNA LNP vaccine-Precision Nanosystems/Tianjin CanSino Biotechnology (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Pharmacodynamics
Sponsors Tianjin CanSino Biotechnology

04 Dec 2024 Status changed from active, no longer recruiting to completed.
19 Oct 2023 Planned End Date changed from 1 Nov 2023 to 1 Dec 2023.
19 Oct 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Dec 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com